Goodwin Procter and Greenberg Traurig have assisted on a USD2.4 billion merger between American biotechnology enterprise Deciphera with ONO, one of the largest pharmaceutical companies in Japan.
Greenberg Traurig is advising ONO Pharmaceutical, led by Chia-Feng Lu and Michael Helsel.
“The scope of this transaction, which involved multiple jurisdictions and a broad array of highly complex corporate and regulatory work, demonstrates the strength of Greenberg Traurig’s global platform in life sciences. I look forward to continuing our work with ONO in the years to come,” said Lu.
Goodwin Procter is acting for Deciphera Pharmaceuticals, led by Stuart Cable, Richard Hoffman, Lisa Haddad and James Ding.
Under the agreement, ONO Pharmaceutical will acquire all outstanding shares of Deciphera’s common stock for USD25.60 apiece, which is expected to close in the third quarter of 2024.
Deciphera, based in Massachusetts, brings specialised research and development capabilities in commercial and sales platforms in the United States and Europe. It focuses on developing and commercialising new medicines to improve the lives of cancer patients.
ONO is a 300-year-old firm committed to delivering innovative new drugs to patients around the world.
